Description
Chonluten (also known as T-34 or EDG) is a synthetic short-chain tripeptide composed of three amino acids: glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly). It belongs to the Khavinson class of peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology.
Core Characteristics and Proposed Mechanism
- Target Tissue: It is primarily studied for its proposed affinity to the respiratory system, specifically lung tissue, the bronchial mucosa, and respiratory epithelial cells.
- Gene Expression: The Khavinson model proposes that Chonluten interacts with DNA promoter regions to modulate gene expression related to cellular maintenance, surfactant production, antioxidant defense (such as superoxide dismutase), and anti-inflammatory pathways.
- Forms Available: It is commonly distributed in research contexts as oral capsules, sublingual drops (Lingual Chonluten®), or lyophilized powder vials that require reconstitution with bacteriostatic water.
Regulatory Status and Safety
- Not Approved Medication: Chonluten is an unapproved research compound and has not received approval from the FDA or major global health authorities for clinical treatment.
- Evidence Limitations: Claims regarding tissue regeneration, lung healing, or anti-aging effects are based largely on preclinical, Russian biogerontology studies, or vendor literature rather than large-scale, peer-reviewed human clinical trials.
Reviews
There are no reviews yet.